1. US National Library of Medicine. Genetics home reference: transthyretin amyloidosis. 2018.
https://ghr.nlm.nih.gov/
. Accessed 16 Aug 2018.
2. Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–38.
3. US FDA. FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease [media release]. 2018.
http://www.fda.gov/
.
4. Alnylam Pharmaceuticals Inc. Onpattro (patisiran) lipid complex injection, for intravenous use: US prescribing information. 2018.
http://www.fda.gov/
. Accessed 16 Aug 2018.
5. Alnylam Netherlands B.V. Onpattro 2 mg/mL concentrate for solution for infusion: EU summary of product characteristics. 2018.
http://www.ema.europa.eu/ema/
. Accessed 5 Sept 2018.